SA
NDRA logo
ENDRA Life Sciences Inc.(NDRA)
Closing price · checked 8:33 PM ETAbout this dataData status
$3.58▼-0.13 (-3.38%)
Extended:$3.50-0.08 (-2.10%)· 8:33 PM ET
11/21/26

ENDRA Life Sciences (NDRA)

Saturday
12:01 AM ET
ThesisPositive clinical trial results and potential partnerships are enhancing investor sentiment towards ENDRA, suggesting a favorable outlook for growth.

Revenue Outlook

★ Analysts see FY2027 revenue reaching $200.0K — +100% growth in a single year.

What’s Driving the Stock

  1. 01Recent clinical trial results showed a 30% improvement in diagnostic accuracy compared to traditional methods, potentially increasing adoption rates.
  2. 02Partnership discussions with a major healthcare provider in the U.S. could lead to a significant distribution agreement, expanding market reach.
  3. 03Potential regulatory approval expected in Q3 2026, which could unlock new revenue streams and validate technology.
  4. 04Growth in non-invasive diagnostic technologies
  5. 05Increased focus on early disease detection
  6. 06Regulatory approvals for TAI technology in key markets
  7. 07Partnerships with healthcare providers or distributors
  8. 08Clinical trial results demonstrating efficacy and safety
FY2025 Snapshot
Revenue
$0.00
NI Growth
+38.9%
EPS
$-8.93
1Y Return
-46.2%

NDRA Chart

3.34.25.16.06.93.58NDRA Daily3.58Jul '26Aug '26Oct '26Nov '26

My Notes

  • "Our innovative technology is on the brink of transforming diagnostic imaging."
  • Moat: ENDRA's proprietary TAI technology provides a unique imaging solution that is difficult for competitors to replicate quickly.
  • growth - Investors looking for high-risk, high-reward opportunities in innovative medical technologies.
  • Interest rates affect ENDRA's financing costs for R&D and operational expenses…
  • Watch on earnings: Regulatory approval timelines for TAI technology, Clinical trial enrollment and results, Sales growth in TAI systems.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $100.0K to $200.0K as recent clinical trial results showed a 30% improvement in diagnostic accuracy compared to traditional methods.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.